ES2129078T3 - Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. - Google Patents
Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion.Info
- Publication number
- ES2129078T3 ES2129078T3 ES93902271T ES93902271T ES2129078T3 ES 2129078 T3 ES2129078 T3 ES 2129078T3 ES 93902271 T ES93902271 T ES 93902271T ES 93902271 T ES93902271 T ES 93902271T ES 2129078 T3 ES2129078 T3 ES 2129078T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical preparation
- beta
- compound capable
- antibiotics
- degrading beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003242 anti bacterial agent Substances 0.000 title abstract 2
- 229940088710 antibiotic agent Drugs 0.000 title abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000593 degrading effect Effects 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01004—Amidase (3.5.1.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
- C12Y305/02006—Beta-lactamase (3.5.2.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyesters Or Polycarbonates (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Cephalosporin Compounds (AREA)
Abstract
LA INVENCION SE REFIERE A UN USO SANITARIO, UN METODO SANITARIO Y UNA PREPARACION FARMACEUTICA. LA INVENCION PERMITE QUE LA ACCION DE ANTIBIOTICOS (BETA)-LACTAMA SE DIRIJA Y SUS EFECTOS LATERALES SE REDUZCAN POR LA INACTIVACION DE PARTE DEL ANTIBIOTICO EN UN SECTOR DESEADO DEL TRACTO DIGESTIVO DISTAL DEL ESTOMAGO ADMINISTRANDO, SEPARADAMENTE DESDE O SIMULTANEAMENTE CON EL ANTIBIOTICO, UNA ENZIMA, COMO (BETA)-LACTAMASA, LA CUAL ROMPE LA RESISTENCIA DE DICHO ANTIBIOTICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI920206A FI920206A0 (fi) | 1992-01-17 | 1992-01-17 | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2129078T3 true ES2129078T3 (es) | 1999-06-01 |
Family
ID=8534042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93902271T Expired - Lifetime ES2129078T3 (es) | 1992-01-17 | 1993-01-18 | Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. |
Country Status (9)
Country | Link |
---|---|
US (1) | US5607671A (es) |
EP (1) | EP0671942B1 (es) |
AT (1) | ATE174513T1 (es) |
DE (1) | DE69322659T2 (es) |
DK (1) | DK0671942T3 (es) |
ES (1) | ES2129078T3 (es) |
FI (1) | FI920206A0 (es) |
GR (1) | GR3029699T3 (es) |
WO (1) | WO1993013795A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041853A1 (fr) * | 1996-05-09 | 1997-11-13 | Sankyo Company, Limited | Compositions de lutte contre helicobacter pylori contenant des derives de 1-methylcarbapenem en tant qu'ingredient actif |
GB2318732A (en) | 1996-11-01 | 1998-05-06 | Johnson & Johnson Medical | Wound healing compositions containing alpha-1-antitrypsin |
FI20020332A0 (fi) * | 2002-02-20 | 2002-02-20 | Heino Pekka Untamo | Valmiste ja menetelmä painon pudottamiseksi |
FR2843302B1 (fr) * | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
FR2843301B1 (fr) * | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
WO2006085075A2 (en) * | 2005-02-09 | 2006-08-17 | Da Volterra | Colonic delivery of active agents |
FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
US8273376B2 (en) * | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
US20080124279A1 (en) * | 2006-11-17 | 2008-05-29 | Antoine Andremont | Colonic delivery using Zn/pectin beads with a Eudragit coating |
MX2009012619A (es) * | 2007-05-21 | 2010-02-12 | Phenomix Corp | Formulacion farmaceutica estable para un inhibidor de dpp-iv. |
ITBO20080297A1 (it) * | 2008-05-16 | 2009-11-17 | Archimede R & D S R L | Composizione enzimatica per ridurre il rilascio di principi attivi farmaceutici nell'ambiente. |
FI20105572A0 (fi) | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
ITMI20121715A1 (it) * | 2012-10-11 | 2014-04-12 | Bioikos Ambiente S R L | Composizioni farmaceutiche con ridotto impatto ambientale |
EP3132033B1 (en) | 2014-04-17 | 2019-10-30 | Synthetic Biologics, Inc. | Beta-lactamases with improved properties for therapy |
JP6803328B2 (ja) | 2014-08-28 | 2021-01-06 | シンセティック バイオロジクス,インコーポレイテッド | 大腸菌ベースでのベータラクタマーゼ生産 |
JP6672277B2 (ja) * | 2014-10-08 | 2020-04-01 | シンセティック・バイオロジクス・インコーポレイテッド | ベータラクタマーゼ製剤およびその使用 |
FR3027307B1 (fr) | 2014-10-16 | 2016-11-04 | Azurrx Sas | Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant |
WO2016105498A1 (en) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
CN107530406B (zh) | 2015-02-23 | 2021-10-22 | 合成生物制品有限公司 | 用于保护肠微生物群系的与抗生素一起使用的碳青霉烯酶 |
AU2016229976B2 (en) | 2015-03-06 | 2021-11-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
BR112018016889A2 (pt) | 2016-02-23 | 2019-02-12 | Da Volterra | variantes de beta-lactamase |
WO2017144495A1 (en) | 2016-02-23 | 2017-08-31 | Da Volterra | Beta-lactamase variants |
CN111247246A (zh) | 2017-10-25 | 2020-06-05 | 达·沃尔泰拉公司 | β-内酰胺酶变体 |
KR20220006072A (ko) * | 2019-05-06 | 2022-01-14 | 신세틱 바이오로직스, 인코퍼레이티드 | 이식편대숙주병의 치료를 위한 베타-락타마제 조성물 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2613624B1 (fr) * | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
CS275231B2 (en) * | 1989-09-29 | 1992-02-19 | Ustav Makormolekularni Chemie | Medicine bottle |
-
1992
- 1992-01-17 FI FI920206A patent/FI920206A0/fi unknown
-
1993
- 1993-01-18 AT AT93902271T patent/ATE174513T1/de not_active IP Right Cessation
- 1993-01-18 DK DK93902271T patent/DK0671942T3/da active
- 1993-01-18 EP EP93902271A patent/EP0671942B1/en not_active Expired - Lifetime
- 1993-01-18 ES ES93902271T patent/ES2129078T3/es not_active Expired - Lifetime
- 1993-01-18 US US08/256,508 patent/US5607671A/en not_active Expired - Lifetime
- 1993-01-18 WO PCT/FI1993/000016 patent/WO1993013795A1/en active IP Right Grant
- 1993-01-18 DE DE69322659T patent/DE69322659T2/de not_active Expired - Fee Related
-
1999
- 1999-03-16 GR GR990400783T patent/GR3029699T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69322659T2 (de) | 2000-01-05 |
GR3029699T3 (en) | 1999-06-30 |
DE69322659D1 (de) | 1999-01-28 |
US5607671A (en) | 1997-03-04 |
EP0671942B1 (en) | 1998-12-16 |
ATE174513T1 (de) | 1999-01-15 |
WO1993013795A1 (en) | 1993-07-22 |
EP0671942A1 (en) | 1995-09-20 |
FI920206A0 (fi) | 1992-01-17 |
DK0671942T3 (da) | 1999-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2129078T3 (es) | Preparacion farmaceutica que comprende un compuesto capaz de degradar los antibioticos beta-lactamicos y su utilizacion. | |
ES2083668T3 (es) | Combinaciones antiviricas que contienen analogos de nucleosidos. | |
ATE169299T1 (de) | Antivirale 2-ethyl-1h-imidazo(4,5-c)chinolin-4- amine | |
DK0466913T3 (da) | Tilslutningsadaptor til katetre | |
BRPI0208957B8 (pt) | composto, uso de um composto, composição farmacêutica e sal | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
IT8723134A0 (it) | Procedimento per la fabbricazione di dispositivi integrati cmos con lunghezze di porta ridotte. | |
ECSP045104A (es) | Ligandos de los receptores de los cannabinoides | |
ID22994A (id) | Senyawa aminoalkil glikosamina fosfat dan penggunaannya sebagai adjuvan dan pemicu kekebalan | |
CO4940450A1 (es) | Formulaciones farmaceuticas que contienen voriconazol | |
ES2184293T3 (es) | Composiciones farmaceuticas administrables por via oral que comprenden una benzhidrilpiperazina y una ciclodextrina. | |
ES2194989T3 (es) | Composicion adminstrada por via oral, que comprende una toxina de zonula occludens y un agente que tiene una actividad biologica, y su utilizacion. | |
HUP9900492A2 (hu) | 3,6-Ketál és enol-éter makrolid antibiotikumok és ezeket tartalmazó gyógyszerkészítmények | |
ES2176698T3 (es) | Nuevos derivados de la eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos. | |
ES2173391T3 (es) | Derivados de 2-aminobenzazepina y su uso para el tratamiento de la inmunodepresion. | |
ATE259823T1 (de) | Tricyclische erythromycinderivate | |
AR026968A1 (es) | Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral | |
AU2005099A (en) | Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections | |
DK0930077T3 (da) | Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat | |
DOP2001000199A (es) | Preparaciones de retardo de antibioticos de quinolona y procedimiento para su fabricación. | |
AU4445089A (en) | Lactamimides in the treatment of drug-resistant protozoal infections | |
ATE388960T1 (de) | Glykopeptidderivate mit carboxysacchariden | |
AR022570A1 (es) | COMPOSICIONES EXTRUIDAS LIVIANAS QUE CONTIENEN UN PORTADOR CERÁMICO LIVIANO EXTRUIBLE, MÉTODOS DE USO DE LAS MISMAS Y PROCESOS PARA SU PREPARACIoN. | |
AR005730A1 (es) | Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato. | |
GT199900153A (es) | Antibiòticos de carbamato y carbamato cetolida.- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 671942 Country of ref document: ES |